Mirum Pharmaceuticals (MIRM) Other Accumulated Expenses (2021 - 2023)

Mirum Pharmaceuticals' Other Accumulated Expenses history runs 3 years deep, the most recent figure standing at $6.7 million for Q4 2023.

• On a quarterly basis, Other Accumulated Expenses rose 173.45% year-over-year to $6.7 million in Q4 2023; TTM through Dec 2023 was $6.7 million, a 173.45% increase from a year earlier, with the FY2023 full-year figure at $6.7 million, up 173.45% from the prior year.
• Other Accumulated Expenses improved to $6.7 million in Q4 2023 per MIRM's latest filing, from $4.4 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $6.7 million in Q4 2023 and bottomed at $345000.0 in Q4 2021.
• The 3-year median for Other Accumulated Expenses is $2.5 million (2022), against an average of $2.7 million.
• Across the five-year window, Other Accumulated Expenses soared 611.88% in 2022 and surged 66.21% in 2023, its largest moves.
• Year by year, Other Accumulated Expenses stood at $345000.0 in 2021, then surged by 611.88% to $2.5 million in 2022, then surged by 173.45% to $6.7 million in 2023.
• Per Business Quant, the three latest MIRM Other Accumulated Expenses figures stand at $6.7 million (Q4 2023), $4.4 million (Q3 2023), and $2.9 million (Q2 2023).